ClinicalTrials.gg
Not yet recruitingNCT06873854Updated Mar 13, 2025

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

A Phase 2 interventional study of LM-108 and Toripalimab in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of LM-108 in combination with Toripalimab in patients with advanced malignant solid tumours with unresectable or metastatic MSI-H/dMMR who have failed previous anti-PD-1 /PD-L1 therapy.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with advanced solid tumors diagnosed by pathology have evidence of advanced stage or that cannot be surgically removed. And the MSI-H status will be confirmed by central laboratory designated of the sponsor.
  2. Aged 18.
  3. (ECOG) performance status of 0-1.
  4. At least one .
  5. Subjects who have failed previous monotherapy with /PD-L1 drugs or combination (synchronous or sequential) with other systemic treatments and unresectable or metastatic late stage MSI-H/dMMR solid tumors.
  6. Subjects must have Archived Samples or fresh tumor tissue specimens are required for testing.
  7. Any adverse event from prior anti-tumor therapy and surgery has recovered to ≤ grade 1 of v5.0.
  8. Subjects must show appropriate organ and marrow function in laboratory examinations.
  9. Women of (WOCBP) and Male participants must agree to use one medically recognized measures of contraception, during the study and for 6 months after the last dose of study drug.
  10. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with symptomatic/active central nervous system (CNS) .
  2. Subject who have uncontrollable pleural effusion, pericardial effusion, and ascites despite treatment such as puncture and drainage Within 14 days prior to enrollment; Pericardial effusion accompanied by clinical symptoms or moderate or above.
  3. Subjects' weight decreased by more than 20% within the first 2 months of enrollment.
  4. Poorly controlled tumor-related pain.
  5. Subjects who received anti-tumour treatment, , major surgery, drugs and before enrollment.
  6. Subjects have received anti-tumor immunotherapy and experienced ≥ grade 3 immune related adverse events (irAE) or ≥ grade 2 immune related myocarditis.
  7. Subjects who have other cancers within 5 years prior to entering the research.
  8. Previous or current known disease.
  9. Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial/venous thrombotic events that occurred within the first 6 months of enrollment.
  10. Present peripheral neuropathy of grade>1 .
  11. Subjects who have a history of gastrointestinal perforation and/or gastrointestinal fistula within the 6 months prior to enrollment.
  12. Subjects who have been clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction Within 6 months prior to starting the study treatment.
  13. Presence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.
  14. Known to be allergic to the drug or any of its ; Or have experienced severe allergic reactions to other monoclonal antibodies.
  15. infection, active or infection.
  16. Subject who have clinical symptoms or diseases of the heart that have not been well controlled.
  17. Subjects who take Systemic use of antibiotics for more than 7 days within the first 4 weeks prior to enrollment, or unexplained fever>38.5 ° C during screening/before first administration .
  18. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  19. Subjects who have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not exceeded 5 half lives since the last study medication.
  20. Known history of abuse or drug use of psychotropic substances.
  21. Subjects who have other serious physical or mental illnesses or laboratory abnormalities and judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    LM-108 in Combination with Toripalimab

    Drug: LM-108 · Drug: Toripalimab

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Overall Response Rate assessed by Independent Review Committee against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: 104 weeks

Secondary outcomes

  1. AEs

    Incidence of adverse events

    Time frame: 104 weeks

  2. SAEs

    Incidence of serious adverse events

    Time frame: 104 weeks

  3. AE/SAE

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 104 weeks

  4. DOR

    Duration of response assessed by Independent Review Committee against the RECIST v1.1

    Time frame: 104 weeks

  5. DCR

    Disease control rate (DCR = CR + PR + SD) assessed by Independent Review Committee against the RECIST v1.1

    Time frame: 104 weeks

  6. PFS

    Progression-free survival assessed by Independent Review Committee against the RECIST v1.1

    Time frame: 104 weeks

  7. Progression-free survival Rates

    Independent Review Committee evaluated the Progression-free survival rates at 3 and 6 months based on RECIST v1.1

    Time frame: 104 weeks

  8. ORR

    Overall Response Rate assessed by investigator against the RECIST v1.1

    Time frame: 104 weeks

  9. DOR

    Duration of response assessed by investigator against the RECIST v1.1

    Time frame: 104 weeks

  10. DCR

    Disease control rate (DCR = CR + PR + SD) assessed by investigator against the RECIST v1.1

    Time frame: 104 weeks

  11. PFS

    Progression-free survival assessed by investigator against the RECIST v1.1

    Time frame: 104 weeks

  12. Progression-free survival Rates

    Investigator evaluated the Progression-free survival rates at 3 and 6 months based on RECIST v1.1

    Time frame: 104 weeks

  13. OS

    Overall survival

    Time frame: 104 weeks

  14. OS rates

    Overall survival rates

    Time frame: 104 weeks

  15. Temperatures

    Temperatures

    Time frame: 104 weeks

  16. Pulse in BPM

    Beat per Minute

    Time frame: 104 weeks

  17. Blood Pressure

    Blood Pressure in mmHg,Both systolic pressure and diastolic pressure

    Time frame: 104 weeks

  18. Weight

    Weight in Kg

    Time frame: 104 weeks

  19. Height

    Height in centimeter

    Time frame: 104 weeks

  20. Complete Blood Count

    Time frame: 104 weeks

  21. Urine Routine test

    Laboratory tests-Urine Routine test

    Time frame: 104 weeks

  22. Blood biochemistry

    Laboratory tests-Blood biochemistry

    Time frame: 104 weeks

  23. Coagulation function

    Laboratory tests-Coagulation function

    Time frame: 104 weeks

  24. Thyroid function

    Laboratory tests-Thyroid function

    Time frame: 104 weeks

  25. Stool routine examination

    Laboratory tests-Stool routine examination

    Time frame: 104 weeks

  26. Virological examination

    Laboratory tests-Virological examination

    Time frame: 104 weeks

  27. Pregnancy check

    Laboratory tests-Pregnancy check

    Time frame: 104 weeks

  28. LVEF

    Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Time frame: 104 weeks

  29. HR

    Electrocardiogram (ECG) in HR

    Time frame: 104 weeks

  30. RR

    Electrocardiogram (ECG) in RR

    Time frame: 104 weeks

  31. PR

    Electrocardiogram (ECG) in PR

    Time frame: 104 weeks

  32. QRS

    Electrocardiogram (ECG) in QRS

    Time frame: 104 weeks

  33. QT

    Electrocardiogram (ECG) in QT

    Time frame: 104 weeks

  34. QTcF

    Electrocardiogram (ECG) in QTcF

    Time frame: 104 weeks

  35. ECOG score

    Eastern Cooperative Oncology Group score

    Time frame: 104 weeks

Other outcomes

  1. iORR

    Immune Overall Response Rate assessed by investigator according to the Immune Response Evaluation Criteria in solid Tumors

    Time frame: 104 weeks

  2. iDOR

    Immune Duration of response assessed by investigator according to the Immune Response Evaluation Criteria in solid Tumors

    Time frame: 104 weeks

  3. iDCR

    Immune Disease control rate assessed by investigator according to the Immune Response Evaluation Criteria in solid Tumors

    Time frame: 104 weeks

  4. iPFS

    Immune Progression-free survival assessed by investigator according to the Immune Response Evaluation Criteria in solid Tumors

    Time frame: 104 weeks

  5. PK Parameter:Ctrough

    PK Parameter:steady state at the end of the dosing interval Concentration

    Time frame: 104 weeks

  6. Immunogenicity testing

    Anti-Drug antibody and Nab (if necessary) will be tested.

    Time frame: 104 weeks

  7. Biomarker correlation

    For the detection of MSI or MMR, and CCR8 and PD-L1

    Time frame: 104 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Jan 2028, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Mar 13, 2025
StartEst.
Mar 26, 2025
Primary completionEst.
Jan 26, 2028
CompletionEst.
Jan 26, 2030
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06873854
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
Mar 26, 2025 (estimated)
Primary completion
Jan 26, 2028 (estimated)
Completion
Jan 26, 2030 (estimated)
Last update
Mar 13, 2025

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211
Paul Kong
Contact
paulkong@lanovamed.com
+8613564682439

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cafelkibart

Start the discussion